Compare CCHH & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CCHH | SGMT |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.1M | 238.7M |
| IPO Year | 2025 | 2023 |
| Metric | CCHH | SGMT |
|---|---|---|
| Price | $14.09 | $6.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $29.75 |
| AVG Volume (30 Days) | ★ 740.6K | 543.4K |
| Earning Date | 12-19-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $8,915,344.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $273.98 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.49 | $1.73 |
| 52 Week High | $14.40 | $11.41 |
| Indicator | CCHH | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 39.68 |
| Support Level | N/A | $5.95 |
| Resistance Level | N/A | $6.55 |
| Average True Range (ATR) | 0.00 | 0.45 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 0.00 | 16.36 |
CCH Holdings Ltd operates a hotpot restaurant chain in Malaysia, specializing in chicken hotpot and fish head hotpot, mainly under two brand, namely Chicken Claypot House and Zi Wei Yuan, owned by the wholly owned subsidiaries of the Company. The Company conducts its operations through its wholly owned subsidiaries in Malaysia and is engaged as a restaurant operator, licensor and loyalty owner, and general trader. Currently, the Group has developed a restaurant chain including approximately 15 company-owned restaurant outlets, 13 franchised restaurant outlets in Malaysia, and 4 franchised restaurant outlets outside Malaysia.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.